WorldCat Identities

Guiguet, Marguerite

Overview
Works: 9 works in 10 publications in 2 languages and 18 library holdings
Roles: Contributor, Author, Other
Publication Timeline
.
Most widely held works by Marguerite Guiguet
Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals by Valérie Martinez( )

2 editions published in 2012 in English and held by 4 WorldCat member libraries worldwide

Le déterminisme de la mitose : modèles mathématiques et analyse statistique de pedigrees de cellules animales en culture by Marguerite Guiguet( Book )

1 edition published in 1980 in French and held by 2 WorldCat member libraries worldwide

Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis by Nadia Valin( )

1 edition published in 2016 in English and held by 2 WorldCat member libraries worldwide

Dual treatment of acute HCV infection in HIV co-infection: influence of HCV genotype upon treatment outcome by The NEAT study group( )

1 edition published in 2015 in English and held by 2 WorldCat member libraries worldwide

Factors Associated with Virological Rebound in HIV-Positive Sub-Saharan Migrants Living in France After Traveling Back to Their Native Country: ANRS-VIHVO 2006-2009 Study by ANRS-VIHVO Study Group( )

1 edition published in 2019 in English and held by 2 WorldCat member libraries worldwide

A critique of the use of DNA synthesis as a measure of the effect of mitogens on lymphocytes by Marguerite Guiguet( )

1 edition published in 1982 in English and held by 2 WorldCat member libraries worldwide

Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals( )

1 edition published in 2015 in English and held by 1 WorldCat member library worldwide

Abstract : Background: HIV-infected individuals with a history of transmission through injection drug use (IDU) have poorer survival than other risk groups. The extent to which higher rates of hepatitis C (HCV) infection in IDU explain survival differences is unclear. Methods: Adults who started antiretroviral therapy between 2000 and 2009 in 16 European and North American cohorts with >70% complete data on HCV status were followed for 3 years. We estimated unadjusted and adjusted (for age, sex, baseline CD4 count and HIV-1 RNA, AIDS diagnosis before antiretroviral therapy, and stratified by cohort) mortality hazard ratios for IDU (versus non-IDU) and for HCV-infected (versus HCV uninfected). Results: Of 32, 703 patients, 3374 (10%) were IDU; 4630 (14%) were HCV+; 1116 (3.4%) died. Mortality was higher in IDU compared with non-IDU [adjusted HR 2.71; 95% confidence interval (CI): 2.32 to 3.16] and in HCV+ compared with HCV− (adjusted HR 2.65; 95% CI: 2.31 to 3.04). The effect of IDU was substantially attenuated (adjusted HR 1.57; 95% CI: 1.27 to 1.94) after adjustment for HCV, while attenuation of the effect of HCV was less substantial (adjusted HR 2.04; 95% CI: 1.68 to 2.47) after adjustment for IDU. Both IDU and HCV were strongly associated with liver-related mortality (adjusted HR 10.89; 95% CI: 6.47 to 18.3 for IDU and adjusted HR 14.0; 95% CI: 8.05 to 24.5 for HCV) with greater attenuation of the effect of IDU (adjusted HR 2.43; 95% CI: 1.24 to 4.78) than for HCV (adjusted HR 7.97; 95% CI: 3.83 to 16.6). Rates of CNS, respiratory and violent deaths remained elevated in IDU after adjustment for HCV. Conclusions: A substantial proportion of the excess mortality in HIV-infected IDU is explained by HCV coinfection. These findings underscore the potential impact on mortality of new treatments for HCV in HIV-infected people. Abstract : Supplemental Digital Content is Available in the Text
 
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.95 (from 0.88 for Hepatic st ... to 0.97 for Hepatic st ...)

WorldCat IdentitiesRelated Identities
Languages